Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 3/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5738405 | 0.99 | PPARG (0.57) | PPARGITGB3ITGA2BCYP3A4RXRA | |
| SCHEMBL14381253 | 0.88 | PPARG (0.54) | PPARGITGB3ITGA2BCYP3A4RXRA | |
| SCHEMBL3313236 | 0.86 | PPARG (0.58) | PPARGITGB3CYP3A4RXRAITGB1 | |
| SCHEMBL13742843 | 0.84 | PPARG (0.54) | PPARGITGB3CYP3A4RXRAITGB1 | |
| SCHEMBL5738702 | 0.84 | PPARG (0.65) | PPARGITGB3ITGA2BCYP3A4RXRA | |
| SCHEMBL2361274 | 0.84 | PPARA (0.61) | PPARGPPARA | |
| SCHEMBL2332479 | 0.84 | PPARA (0.61) | PPARGPPARA | |
| SCHEMBL13475126 | 0.84 | PPARG (0.69) | PPARGITGB3ITGA2BCYP3A4RXRA | |
| SCHEMBL2332774 | 0.84 | PPARA (0.61) | PPARGPPARA | |
| SCHEMBL14213074 | 0.84 | PPARG (0.52) | PPARGCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375231-B2 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM S.A. (ES) | 2008-05-20 | — | — | US | disclosed |
| US-7375231-B2 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM S.A. (ES) | 2008-05-20 | — | — | US | disclosed |
| US-7375231-B2 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM S.A. (ES) | 2008-05-20 | — | — | US | disclosed |
| EP-1623977-B1 | INTERMEDIATE COMPOUND WHICH IS USED FOR THE PREPARATION OF PIOGLITAZONE | MEDICHEM SA (ES) | 2007-11-07 | — | — | EP | disclosed |
| EP-1623977-B1 | INTERMEDIATE COMPOUND WHICH IS USED FOR THE PREPARATION OF PIOGLITAZONE | MEDICHEM SA (ES) | 2007-11-07 | — | — | EP | disclosed |
| US-20070083050-A1 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM, S.A. (ES) | 2007-04-12 | — | — | US | disclosed |
| US-20070083050-A1 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM, S.A. (ES) | 2007-04-12 | — | — | US | disclosed |
| US-20070083050-A1 | Intermediate compound which is used for the preparation of pioglitazone | MEDICHEM, S.A. (ES) | 2007-04-12 | — | — | US | disclosed |
| EP-1622898-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | Synthon B.V. (NL) | 2006-02-08 | — | — | EP | disclosed |
| EP-1623977-A1 | INTERMEDIATE COMPOUND WHICH IS USED FOR THE PREPARATION OF PIOGLITAZONE | Medichem, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | SYNTHON BV (NL) | 2005-03-17 | — | — | US | disclosed |
| WO-2004101560-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | SYNTHON B.V. (NL) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083050-A1 | Intermediate compound which is used for the preparation of pioglitazone | GLP1R, JAK2, GPR119 | PPARG 28/4885ITGB3 2374/4885ITGA2B 1775/4885 |
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | PPARD, PPARG, PPARA | PPARG 2/4885ITGB3 2321/4885ITGA2B 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.